17
ELV
ELEVANCE HEALTH INC FORMERLY · Financials
Consensus score 17/100 · #37 this quarter · tier-weighted across tracked managers
↑ConfirmedPrice action since filingas of 2026-10-14
vs 50-day avg
+7.0%
21-day momentum
+2.5%
recent volume
1.02×
13F filings lag ~45 days; this is current price/volume action on top — a technical read, not a prediction.
S2· AdvancingStage Analysis · Weinstein
vs 30-wk avg
+15.2%
30-wk MA slope
+2.5%
rel. strength
+4.7
52-wk range
95%
Advancing — above a rising 30-week trend with positive relative strength. Weinstein’s buy zone. Based on the 30-week (150-day) moving average + slope, Mansfield relative strength vs SPY, and volume. Technical read, not advice.
Holders
9
tracked managers
New this Q
1
opened a position
Avg weight
3.3%
of their portfolios
Combined value
$2.05B
held, at quarter-end
Who’s holding it Q2 2026, by position size
| Manager | Position size | Value | Change |
|---|---|---|---|
| Baupost Group Deep value | 9.1% | $493M | HOLD |
| Brave Warrior Concentrated | 8.2% | $378M | TRIM |
| Ruane Cunniff / Sequoia Quality compounder | 5.9% | $379M | TRIM |
| Hosking Partners Concentrated | 1.9% | $58M | TRIM |
| Eagle Capital Quality value | 1.8% | $577M | TRIM |
| Yacktman Asset Management Quality value | 1.6% | $131M | ADD |
| Glenview Capital Concentrated | 0.5% | $26M | NEW |
| Tweedy Browne Graham/global value | 0.2% | $2M | ADD |
| Hound Partners Concentrated | 0.1% | $949K | TRIM |
Position size = share of that manager’s reported long US-equity portfolio. The consensus score weights each holder by quality tier, position size, and whether they were buying or trimming — then discounts very crowded names. It measures agreement among these managers, not expected return.